TG Therapeutics TGTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.92M+6.4% | $192.57M+19.1% | $161.71M+14.6% | $141.15M+16.8% | $120.86M+11.7% | ||
| $33.51M-12.1% | $38.14M+35.8% | $28.09M+48.3% | $18.94M+21.9% | $15.54M+0.9% | ||
| $171.41M+11.0% | $154.43M+15.6% | $133.62M+9.3% | $122.21M+16.0% | $105.32M+13.5% | ||
| 83.6%+3.5pp | 80.2%-2.4pp | 82.6%-4.0pp | 86.6%-0.6pp | 87.1%+1.4pp | ||
| $48.4M+17.5% | $41.19M+0.8% | $40.88M+28.6% | $31.78M-31.4% | $46.36M+94.2% | ||
| $88.22M+40.6% | $62.75M-1.0% | $63.37M+14.0% | $55.59M+10.4% | $50.33M+29.2% | ||
| $73.14M+44.2% | $50.73M-0.6% | $51.02M+17.2% | $43.54M+12.5% | $38.69M+28.2% | ||
| $170.12M+19.7% | $142.08M+7.4% | $132.34M+24.5% | $106.31M-5.3% | $112.23M+43.5% | ||
| $34.8M-31.1% | $50.49M+72.0% | $29.37M-15.7% | $34.84M+304% | $8.62M-71.2% | ||
| 17%-9.2pp | 26.2%+8.1pp | 18.2%-6.5pp | 24.7%+17.6pp | 7.1%-20.5pp | ||
| $7.67M+17.3% | $6.53M-2.8% | $6.72M+0.1% | $6.72M-0.6% | $6.76M-4.3% | ||
| -$14.43M-167% | -$5.4M-56.3% | -$3.46M+11.9% | -$3.92M-24.4% | -$3.15M+29.8% | ||
| -$9.15M— | $0— | —— | —— | $0+100% | ||
| $20.36M-54.8% | $45.09M+74.0% | $25.91M-16.2% | $30.92M+465% | $5.47M-78.5% | ||
| $586K— | $0+100% | -$364.99M-13,455% | $2.73M+570% | $408K-80.8% | ||
| $19.78M-14.2% | $23.04M-94.1% | $390.9M+1,287% | $28.19M+457% | $5.06M-78.3% | ||
| 9.7%-2.3pp | 12%-230pp | 241.7%+222pp | 20%+15.8pp | 4.2%-17.4pp | ||
| $0.12-20.0% | $0.15-93.8% | $2.43+1,329% | $0.17+467% | $0.03-80.0% | ||
| $0.14-30.0% | $0.20-92.6% | $2.69+1,316% | $0.19+533% | $0.03-81.3% | ||
| 160.1M-0.8% | 161.4M+0.3% | 161M-1.0% | 162.6M-0.1% | 162.8M+1.5% | ||
| 144.4M+0.1% | 144.3M-0.8% | 145.4M-0.9% | 146.7M0.0% | 146.7M+0.9% | ||
| $4.88M+34.1% | $3.63M-31.9% | $5.34M+23.6% | $4.32M+29.6% | $3.33M+5.4% | ||
| $15.08M+25.4% | $12.02M-2.7% | $12.35M+2.5% | $12.04M+3.5% | $11.64M+32.5% | ||
| $2.39M+111% | $1.13M-65.3% | $3.27M+16.9% | $2.79M-22.5% | $3.6M+40.5% | ||
| $43.52M+15.9% | $37.56M+5.7% | $35.54M+29.4% | $27.46M-36.2% | $43.03M+108% | ||
| $204.92M+6.4% | $192.57M+19.1% | $161.71M+14.6% | $141.15M+16.8% | $120.86M+11.7% | ||
| $34.8M-31.1% | $50.49M+72.0% | $29.37M-15.7% | $34.84M+304% | $8.62M-71.2% | ||
| $34.83M-31.1% | $50.52M+71.9% | $29.38M-15.7% | $34.86M+304% | $8.63M-71.2% | ||
| $34.83M-31.1% | $50.52M+71.9% | $29.38M-15.7% | $34.86M+304% | $8.63M-71.2% | ||
| 17%-9.2pp | 26.2%+8.1pp | 18.2%-6.5pp | 24.7%+17.6pp | 7.1%-20.6pp | ||
| $34.8M-31.1% | $50.49M+72.0% | $29.37M-15.7% | $34.84M+304% | $8.62M-71.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
